COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor

Abstract

The SARS-CoV-2 spread quickly across the globe. The World Health Organization (WHO) on March 11 declared COVID-19 a pandemic. The mortality rate, hospital disorders and incalculable economic and social damages, besides the unproven efficacy of the treatments evaluated against COVID-19, raised the need for immediate control of this disease. Therefore, the current study employed in silico tools to rationally identify new possible SARS-CoV-2 main protease (Mpro) inhibitors. That is an enzyme conserved among the coronavirus species; hence, the identification of an Mpro inhibitor is to make it a broad-spectrum drug. Molecular docking studies described the binding sites and the interaction energies of 74 Mpro-ligand complexes deposited in the Protein Data Bank (PDB). A structural similarity screening was carried out in order to identify possible Mpro ligands that show additional pharmacological properties against COVID-19. We identified 59 hit compounds and among them, melatonin stood out due to its prominent immunomodulatory and anti-inflammatory activities; it can reduce oxidative stress, defence cell mobility and efficiently combat the cytokine storm and sepsis. In addition, melatonin is an inhibitor of calmodulin, an essential intracellular component to maintain angiotensin-converting enzyme 2 (ACE-2) on the cell surface. Interestingly, one of the most promising hits in our docking study was melatonin. It revealed better interaction energy with Mpro compared to ligands in complexes from PDB. Consequently, melatonin can have response potential in early stages for its possible effects on ACE-2 and Mpro, although it is also promising in more severe stages of the disease for its action against hyper-inflammation. These results definitely do not confirm antiviral activity, but can rather be used as a basis for further preclinical and clinical trials.

Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections

“…184 Furthermore, in silico studies suggest that melatonin inhibits SARS-CoV-2's main protease. 185 It has therefore been suggested that melatonin could be used as prophylaxis or treatment in COVID-19. 186 187 A randomised trial to evaluate the efficacy of melatonin for prophylaxis against SARS-CoV-2 infection in healthcare workers is ongoing.…”

SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention

“…These receptors intervene by activating the renin–angiotensin–aldosterone system (RAAS) and contribute to the appearance of severe lung damage [ 225 ].Furthermore, in vitro studies reported that melatonin inhibits the SARS-CoV-2 major protease (Mpro). The Mpro is an ever present enzyme among the coronavirus species; thus, melatonin identifying itself as an inhibitor of Mpro would become a broad spectrum drug of SARS-CoV-2 [ 226 ]. Moreover, the bats, the main reservoirs of coronavirus, have almost no symptoms associated to the viral infection [ 227 ].…”

Can Melatonin Be a Potential “Silver Bullet” in Treating COVID-19 Patients?

“…The main protease of SARS-CoV-2 is an enzyme conserved among the coronavirus species. By using in silico tools to identify new possible SARS-CoV-2 main protease inhibitors, molecular docking studies described the binding sites and the interaction energies of 74 ligand complexes [ 10 ]. Melatonin revealed better interaction energy with the SARS-CoV-2 main protease than the other ligands.…”